XFB-19
/ Xfibra
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 02, 2026
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Xfibra, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human
January 10, 2026
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Xfibra, Inc. | Trial completion date: Mar 2023 ➔ Dec 2026 | Trial primary completion date: Jan 2023 ➔ Sep 2026
First-in-human • Trial completion date • Trial primary completion date
July 19, 2022
A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Xfibra, Inc. | Trial completion date: Dec 2022 ➔ Mar 2023 | Initiation date: May 2022 ➔ Aug 2022 | Trial primary completion date: Sep 2022 ➔ Jan 2023
Trial completion date • Trial initiation date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
May 05, 2022
A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Xfibra, Inc.
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1